{"id":"epoetin-beta-neorecormon","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Hypertension"},{"rate":"5-15%","effect":"Headache"},{"rate":"5-10%","effect":"Arthralgia"},{"rate":"5-10%","effect":"Injection site reactions"},{"rate":"1-5%","effect":"Thrombotic events (venous thromboembolism)"},{"rate":"<1%","effect":"Pure red cell aplasia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin beta is a glycoprotein produced by recombinant DNA technology that mimics endogenous erythropoietin (EPO). It binds to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity of the blood.","oneSentence":"Epoetin beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:39.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients with HIV infection receiving antiretroviral therapy"},{"name":"Perioperative anemia in patients undergoing elective surgery"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"NEPHROGENIC SYSTEMIC FIBROSIS"},{"count":2,"reaction":"ERYTHEMA"},{"count":2,"reaction":"HAEMODIALYSIS"},{"count":2,"reaction":"OEDEMA PERIPHERAL"},{"count":2,"reaction":"PAIN IN EXTREMITY"},{"count":1,"reaction":"AORTIC ARTERIOSCLEROSIS"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"CARDIOMEGALY"},{"count":1,"reaction":"COLON CANCER"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"epoetin beta [NeoRecormon]","genericName":"epoetin beta [NeoRecormon]","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients with HIV infection receiving antiretroviral therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}